Live Markets
Tuesday, October 27, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets

Silexion Therapeutics Corp (SLXNW)

NCM

$0.01-0.00 (-41.41%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
—
P/E (TTM)
—
EPS
—
Div Yield
—
52W Range
$0.01–$0.01
Beta
-0.30

Company overview

Silexion Therapeutics Corp, a clinical-stage biotechnology company, discovers and develops RNA interference (RNAi) therapies for KRAS-driven cancers. Its products comprise SIL204 second-generation small interfering RNA (siRNA) undergoing phase 2/3 clinical evaluation for pancreatic cancer and silence mutant KRAS oncogene expression. The company was founded in 2008 and is headquartered in Ramat Gan, Israel.

13 employeessilexion.com

Peers in industry

Silexion Therapeutics Corp has no peer companies in this window.

Recent press releases

Silexion Therapeutics Corp has not issued a press release in this window.

SEC filings

All filings →

Silexion Therapeutics Corp has not filed an SEC document in this window.

Silexion Therapeutics Corp has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
11,111 sh0.0%
337,500 sh0.0%
236,546 sh0.0%
218,965 sh-0.3%

People at Silexion Therapeutics Corp

All people →

No officers or directors have been indexed for Silexion Therapeutics Corp.

Quarterly financials

Full financials →
Revenue trend
03/25
—
NI -$1.7M
06/25
—
NI -$2.5M
09/25
—
NI -$3.3M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $2.88
Prior: $4.32
Revenue sparkline